Brief: Akeso's Cadonilimab Met Primary Endpoint Of Progression-Free Survival In Phase III Trial For First-Line Treatment Of Recurrent/Metastatic Cervical Cancer In All-Comer Patients
27/11/2023 15:23
Nov 27 (Reuters) - Akeso Inc 9926.HK :
* CADONILIMAB (PD-1/CTLA-4 BISPECIFIC ANTIBODY) MET PRIMARY
ENDPOINT OF PROGRESSION-FREE SURVIVAL IN PHASE III TRIAL FOR
FIRST-LINE TREATMENT OF RECURRENT/METASTATIC CERVICAL CANCER IN
ALL-COMER PATIENTS
* AKESO: SAFETY PROFILE OF CADONILIMAB REMAINS CONSISTENT
WITH
PREVIOUS CLINICAL RESULTS WITH NO NEW SAFETY SIGNALS IDENTIFIED
Source text for Eikon: ID:nPn71D5F9a
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals